ArticleTransfusion2012
Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need.
Article in Transfusion, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Burden of myelodysplastic syndromes: a systematic literature review of economic burden.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Pooled it
- Impact of Transfusion Dependence on Clinical and Economic Burden in Patients with Lower-Risk Myelodysplastic Syndromes: A 28-Year Retrospective Study.Journal of blood medicine · 2026Article
- Economic Burden of treated Lower-Risk Myelodysplastic Syndromes in France: A Population-Based Study.ClinicoEconomics and outcomes research : CEOR · 2026Article
- Development of luspatercept to treat ineffective erythropoiesis.Blood advances · 2021Article
- Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies.HemaSphere · 2019Review
- Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States.PharmacoEconomics - open · 2019Article
- Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome.Journal of internal medicine · 2017Article
- Value of transfusion independence in severe aplastic anemia from patients' perspectives - a discrete choice experiment.Journal of patient-reported outcomes · 2017Article
- Beyond the Niche: Myelodysplastic Syndrome Topobiology in the Laboratory and in the Clinic.International journal of molecular sciences · 2016Review
- Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes.Anemia · 2016Review
- Article
- Incidence and Burden of the Myelodysplastic Syndromes.Current hematologic malignancy reports · 2015Review
- Stopping higher-risk myelodysplastic syndrome in its tracks.Current hematologic malignancy reports · 2014Review
- Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with/without transfusions, and with/without active therapy.Leukemia & lymphoma · 2014Article
- Costs and quality of life in patients with myelodysplastic syndromes.American journal of blood research · 2013Article
- Iron chelation therapy in patients with transfusion-dependent myelodysplastic syndrome.Transfusion · 2012Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent retrospective studies suggest myelodysplastic syndromes (MDSs) are more common than previously recognized and patients who develop transfusional dependence may be at risk for increased comorbid complications. STUDY DESIGN AND
methodsA retrospective review was undertaken of Medicare claims focusing on costs associated with patients with a new claim listing ICD-9-CM Diagnosis Code 238.7 in first quarter of 2003. Patients were followed until 2005 to assess resource use and costs.
resultsA total of 512 patients aged 65 years or more with newly diagnosed MDS were identified. Forty percent had received red blood cell transfusions between 2003 and 2005. During the 3-year follow-up, transfused patients experienced increased prevalence of cardiac diseases, dyspnea, and infections. Cumulative 3-year mean Medicare costs for MDS patients were $49,156. Transfused patients had greater use of hospital inpatient and outpatient services and incurred significantly higher mean costs than nontransfused patients ($88,824 vs. $29,519, p < 0.001). After adjustment for baseline characteristics and clinical complications, transfusion was independently associated with a 48% increase in monthly costs in addition to the cost of transfusion administration.
conclusionMDS places a significant economic burden on the US Medicare system. MDS patients requiring transfusions experience higher prevalence of new comorbid conditions and incur significantly higher Medicare costs than nontransfused patients during the initial 3 years after diagnosis.
Indexed as
Identifiers
22486790What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.